DNMT3A P569_A574del
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene DNMT3A
Variant P569_A574del
Impact List deletion
Protein Effect unknown
Gene Variant Descriptions DNMT3A P569_A574del results in the deletion of six amino acids in the ADD domain of the Dnmt3a protein from amino acids 569 to 574 (UniProt.org). P569_A574del has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Oct 2025).
Associated Drug Resistance
Category Variants Paths

DNMT3A mutant DNMT3A P569_A574del

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_022552.5
gDNA chr2:g.25244284_25244301del18
cDNA c.1705_1722del18
Protein p.P569_A574delPGAAQA
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001320893.1 chr2:g.25240448_25240654del207 c.1706_1723del207 p.K569_G574delKGLYEG RefSeq GRCh38/hg38
XM_011532666.3 chr2:g.25240374_25240391del18 c.1705_1722del18 p.E569_P574delEGDDRP RefSeq GRCh38/hg38
NM_022552 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_011532664 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_005264175.6 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574delPGAAQA RefSeq GRCh38/hg38
NM_001375819.1 chr2:g.25239148_25239165del18 c.1706_1723del18 p.R569_N574delRYFWGN RefSeq GRCh38/hg38
XM_005264175.5 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_047443594.1 chr2:g.25240423_25240440del18 c.1705_1722del18 p.R569_F574delRLFFEF RefSeq GRCh38/hg38
NM_175629 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_011532664.3 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574delPGAAQA RefSeq GRCh38/hg38
XM_017003526.1 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_017003526 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_047443597.1 chr2:g.25239148_25239165del18 c.1706_1723del18 p.R569_N574delRYFWGN RefSeq GRCh38/hg38
XM_047443596.1 chr2:g.25239148_25239165del18 c.1706_1723del18 p.R569_N574delRYFWGN RefSeq GRCh38/hg38
NM_022552.4 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
NM_175629.2 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574delPGAAQA RefSeq GRCh38/hg38
NM_153759.3 chr2:g.25240336_25240353del18 c.1705_1722del18 p.V569_V574delVVAMGV RefSeq GRCh38/hg38
XM_011532662.3 chr2:g.25243965_25243982del18 c.1705_1722del18 p.D569_Y574delDPPKVY RefSeq GRCh38/hg38
XM_005264175 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
NM_175629.2 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_011532667.4 chr2:g.25239148_25239165del18 c.1706_1723del18 p.R569_N574delRYFWGN RefSeq GRCh38/hg38
XM_011532664.2 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574del RefSeq GRCh38/hg38
XM_017003527.2 chr2:g.25239148_25239165del18 c.1706_1723del18 p.R569_N574delRYFWGN RefSeq GRCh38/hg38
NM_022552.5 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574delPGAAQA RefSeq GRCh38/hg38
XM_047443592.1 chr2:g.25241625_25241642del18 c.1705_1722del18 p.D569_G574delDSITVG RefSeq GRCh38/hg38
XM_047443598.1 chr2:g.25239148_25239165del18 c.1706_1723del18 p.R569_N574delRYFWGN RefSeq GRCh38/hg38
XM_047443593.1 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574delPGAAQA RefSeq GRCh38/hg38
XM_017003526.2 chr2:g.25244284_25244301del18 c.1705_1722del18 p.P569_A574delPGAAQA RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DNMT3A mutant myelofibrosis not applicable N/A Guideline Prognostic DNMT3A mutations are associated with inferior overall survival in patients with primary myelofibrosis (NCCN.org). detail...
DNMT3A mutant acute myeloid leukemia not applicable N/A Clinical Study Prognostic In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448). 22490330 21881046 21670448
DNMT3A mutant acute myeloid leukemia sensitive Pinometostat Preclinical - Cell line xenograft Actionable In a preclinical study, Pinometostat (EPZ-5676) treatment of acute myeloid leukemia cell lines and xenografts resulted in apoptosis, cell-cycle arrest, and terminal differentiation (PMID: 27335278). 27335278
DNMT3A mutant acute myeloid leukemia predicted - sensitive Decitabine Clinical Study - Cohort Actionable In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to patients with wild-type DNMT3A when treated with frontline hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649). 27418649
DNMT3A mutant angioimmunoblastic T-cell lymphoma not applicable N/A Guideline Diagnostic DNMT3A mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org). detail...
DNMT3A mutant acute myeloid leukemia resistant Olaparib Preclinical - Patient cell culture Actionable In a preclinical study, patient-derived acute myeloid leukemia cells harboring a DNMT3A mutation along with FLT3-ITD and NPM1 mutation were resistant to Lynparza (olaparib) in culture (PMID: 34215619). 34215619